Precipio Announces Year end 2023 Shareholder Update Call
25 mars 2024 17h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at...
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
13 févr. 2024 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown...
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
06 févr. 2024 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for...
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
23 janv. 2024 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that continued revenue growth generated cash levels that bring the...
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
17 janv. 2024 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the...
Precipio Announces Christina Valauri joins the Board of Directors
02 janv. 2024 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is pleased to welcome Christina Valauri to its board of directors effective Jan...
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
14 déc. 2023 16h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and reflections looking back at 2023, and forward...
Precipio Announces Q3-2023 Shareholder Update Call
16 nov. 2023 17h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at...
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
18 oct. 2023 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from...
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
03 oct. 2023 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives...